CleanSpace Holdings Valuation

Is CSX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CSX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CSX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CSX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CSX?

Key metric: As CSX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CSX. This is calculated by dividing CSX's market cap by their current revenue.
What is CSX's PS Ratio?
PS Ratio	1.8x
Sales	AU$15.72m
Market Cap	AU$28.46m

CSX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.4x
Enterprise Value/EBITDA	-5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does CSX's PS Ratio compare to its peers?

The above table shows the PS ratio for CSX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.6x
AT1 Atomo Diagnostics	3.1x	n/a	AU$12.8m
UBI Universal Biosensors	4.8x	n/a	AU$34.3m
LBT Clever Culture Systems	25.2x	n/a	AU$31.6m
EYE Nova Eye Medical	1.4x	26.3%	AU$33.2m
CSX CleanSpace Holdings	1.8x	n/a	AU$28.5m

Price-To-Sales vs Peers: CSX is good value based on its Price-To-Sales Ratio (1.8x) compared to the peer average (8.6x).

Price to Sales Ratio vs Industry

How does CSX's PS Ratio compare vs other companies in the AU Medical Equipment Industry?

9 Companies	Price / Sales	Estimated Growth	Market Cap
SDI SDI	1.1x	5.4%	US$81.57m
SOM SomnoMed	0.7x	9.0%	US$39.36m
CMP Compumedics	1x	n/a	US$32.28m
NXS Next Science	1.1x	30.6%	US$25.66m

9 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: CSX is good value based on its Price-To-Sales Ratio (1.8x) compared to the Australian Medical Equipment industry average (4.1x).

Price to Sales Ratio vs Fair Ratio

What is CSX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CSX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CSX's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

SDI

AU$125.4m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.06

-1.9%

33.5%

CardieX

AU$30.9m

Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific.

CDX

AU$0.10

-12.5%

n/a

Nova Eye Medical

AU$33.2m

Designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally.

EYE

AU$0.14

-3.3%

11.5%